Newron Pharma Delays Schizophrenia Trials Over Safety Concerns (Evanamide)

[firemonkey]

Newron sees promise in schizophrenia drug , Evanamide

Treatment with evenamide was generally well-tolerated, although two patients discontinued treatment due to seizure and atrial fibrillation, respectively. The study was designed to assess safety and preliminary efficacy. Evenamide, an oral drug, has a different mechanism of action to other available antipsychotics. It is in development as an add-on to existing schizophrenia treatments, and the company hopes that it will have potential to address harder-to-treat negative symptoms of the disease.